Idecabtagene Vicleucel



bb2121 is a study treatment that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This type of therapy involves T-cells being taken from the patient and being modified to be able to recognize myeloma tumor cells more easily. 

SparkCures ID 236
Developed By bluebird bio
Brand Name Abecma®
Generic Name Idecabtagene Vicleucel
Additional Names bb2121, ide-cel
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Highly Refractory Myeloma Has Deep and Durable Responses With Ide-cel

December 05, 2020

The objective response rate (ORR) in the entire treated patient population (N = 62) was 75.8% with a rate of complete response (CR) or greater of 38.7%. All 15 patients who achieved a CR or greater and had bone marrow evaluable for minimal residual disease (MRD) demonstrated MRD negativity by next-generation sequencing.


The most common any-grade and grade 3/4 adverse effects observed were cytopenias. Neutropenia of any grade occurred in 91.9% of patients, anemia in 75.8%, thrombocytopenia in 74.2%, leukopenia in 64.5%, and lymphopenia in 37.1%. Corresponding rates of grade 3/4 cytopenias were 88.7%, 56.5%, 56.5%, 61.3%, and 35.5%, respectively. In patients without blood count recovery within 1 month, median recovery times for neutropenia and thrombocytopenia were 1.9 months and 2.2 months, respectively.